Last reviewed · How we verify
Administration of Azithromycin on Day 1
Azithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.
Azithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. Used for Bacterial infections (respiratory tract, skin and soft tissue, sexually transmitted infections), Atypical infections (Mycoplasma, Chlamydia, Legionella).
At a glance
| Generic name | Administration of Azithromycin on Day 1 |
|---|---|
| Sponsor | London School of Hygiene and Tropical Medicine |
| Drug class | Macrolide antibiotic |
| Target | Bacterial 50S ribosomal subunit |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Azithromycin binds to the bacterial 50S ribosomal subunit and inhibits transpeptidation and translocation, thereby preventing peptide bond formation and halting protein synthesis. This bacteriostatic action is effective against a broad spectrum of gram-positive and gram-negative bacteria, as well as atypical organisms. The drug accumulates in tissues and has a long half-life, allowing for convenient dosing schedules.
Approved indications
- Bacterial infections (respiratory tract, skin and soft tissue, sexually transmitted infections)
- Atypical infections (Mycoplasma, Chlamydia, Legionella)
Common side effects
- Gastrointestinal disturbance (nausea, diarrhea, abdominal pain)
- Headache
- Vaginitis
- QT prolongation
- Hepatotoxicity
Key clinical trials
- Azithromycin Reduction to Reach Elimination of Trachoma (PHASE4)
- An Adaptive Multi-arm Trial to Improve Clinical Outcomes Among Children Recovering From Complicated SAM (PHASE3)
- Azithromycin Reduction to Reach Elimination of Trachoma B (PHASE4)
- Scrub Typhus Antibiotic Resistance Trial (PHASE4)
- Doxycycline vs. Macrolide for MRMP (DOMINO) (PHASE4)
- Periodic Presumptive Treatment vs. doxyPEP for STI Control in Kenyan MSM (PHASE4)
- Combined Diagnostic Approach for Refractory Mycoplasma Pneumonia in Children (NA)
- Effect of Topical Azithromycin on Tear Film Thickness in Patients With Meibomian Gland Dysfunction (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: